SAB Biotherapeutics, Inc. SABS
Biological Products, (No Diagnostic Substances) · CIK 0001833214 · Fiscal year ends 1231
Revenue
$0
Fiscal year ended 2025-12-31Operating income
-$48.95M
Fiscal year ended 2025-12-31Free cash flow
-$45.71M
Fiscal year ended 2025-12-31Valuation, from the filing
| Public float | $76.73M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|
| Float per share | $1.51 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
|---|
| Float / net income | 5.8× | A lower bound on the multiple, because affiliate holdings are excluded. |
|---|
| Float / equity | 0.5× | A lower bound on the multiple, because affiliate holdings are excluded. |
|---|
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
How this compares in its industry
Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
SAB Biotherapeutics, Inc. (SABS) reported revenue of $0 and net income of $13.27M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from SAB Biotherapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).
Income
Balance
Cash flow
Derived
SAB Biotherapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|
| Free cash flow | -$45.71M | -$34.63M | -$25.32M | -$25.63M | -$8.96M | -$2.73M |
|---|
| Gross margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Operating margin | —Unavailable | -3244.9% | -1700.6% | -121.0% | -22.0% | 37.2% |
|---|
| FCF margin | —Unavailable | -2618.6% | -1130.7% | -107.2% | -14.7% | -4.9% |
|---|
| SBC / revenue | —Unavailable | 222.5% | 108.3% | 11.2% | 3.8% | 2.3% |
|---|
| Current ratio | 9.46x | 2.98x | 5.45x | 1.47x | 1.90x | 3.11x |
|---|
| Revenue YoY growth | -100.0% | -40.9% | -90.6% | -60.7% | 10.2% | —Unavailable |
|---|
| Net margin | —Unavailable | -2579.0% | -1884.5% | -78.4% | -28.2% | 36.4% |
|---|
| R&D / revenue | —Unavailable | 2287.6% | 737.6% | 152.4% | 93.9% | 50.5% |
|---|
| CapEx / revenue | —Unavailable | 25.5% | 8.8% | 9.1% | 18.0% | 23.0% |
|---|
| Long-term debt / equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Effective tax rate | 0.0% | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SABS in the interactive workspace to inspect any figure back to its filing.
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.